In a multiple hit paradigm, patients with the CBR3 GG genotype previously treated with DOX may develop earlier and more severe cardiomyopathy than patients with the CBR3 AA or AG genotypes after undergoing any additional cardiac insult (i.e., exposure to other cytotoxic agents or development of ischemic heart disease). Here, CBR3 is linked to coronary artery disorder.